What is the appropriate evaluation and management of persistent fever in a patient with myelodysplastic syndrome?

Management of Persistent Fever in Myelodysplastic Syndrome

In patients with MDS and persistent fever, maintain the initial empirical broad-spectrum antibiotic regimen without modification if the patient remains hemodynamically stable and clinically unchanged, as persistent fever alone (median time to defervescence is 5 days in hematologic malignancies) does not warrant antibiotic escalation unless guided by clinical deterioration or positive cultures. 1

Initial Evaluation and Risk Stratification

When fever develops in an MDS patient, immediately assess:

• Absolute neutrophil count (ANC): Neutropenia (≤1,000 neutrophils/μL) is an independent risk factor for infection in MDS, with infection rates increasing as ANC decreases 2
• MDS subtype: Infection risk stratifies as RA±RS < RAEB < RAEB-T, with higher-risk subtypes experiencing more frequent infections 2
• Clinical stability: Hemodynamic parameters, new symptoms, or organ dysfunction 1

Infection is the most common cause of death in MDS (64% of deaths), exceeding transformation to acute leukemia, making aggressive evaluation mandatory. 2

Diagnostic Workup

Focus evaluation on the most common infection sites in MDS:

• Bacterial pneumonia (most common infection) 2
• Skin and soft tissue abscesses (second most common) 2
• Blood cultures before antibiotic initiation 1
• Chest imaging for respiratory symptoms 3
• Examination of all skin sites, including catheter insertion sites 2

Consider non-infectious causes in stable patients with prolonged fever:

• Drug-related fever 1
• The underlying MDS itself (particularly with monocytosis and markedly elevated ferritin >1,000 μg/L) 4
• Thrombophlebitis 1
• Blood resorption from hematomas 1

Management During Days 2-4 of Persistent Fever

Do not modify antibiotics based on fever pattern alone in stable patients. 1 The median time to defervescence in hematologic malignancies is 5 days, so persistent fever through day 4-5 is expected 1.

For Hemodynamically Stable Patients:

• Continue initial empirical regimen unchanged 1
• Monitor daily for clinical deterioration or new localizing signs 1
• Repeat cultures only if clinical change occurs 1

Avoid These Common Pitfalls:

• Do not add vancomycin empirically for persistent fever alone: A randomized trial showed no benefit in time-to-defervescence when vancomycin was added to piperacillin-tazobactam at 60-72 hours 1
• Do not switch between monotherapies without clinical indication 1
• Do not add aminoglycosides empirically unless expanded spectrum coverage is needed based on clinical or microbiologic data 1
• If vancomycin was started empirically, discontinue it after 48 hours if blood cultures show no gram-positive organisms 1

When to Modify Antibiotics

Change the regimen only when:

• Documented infection identified: Tailor antibiotics to specific pathogens and local susceptibility patterns 1
• Clinical deterioration: New hypotension, respiratory distress, altered mental status, or new organ dysfunction 1
• Positive cultures: Adjust based on organism identification and sensitivities 1

Duration of Therapy

• Continue antibiotics until ANC recovers to >500 cells/mm³ in patients with unexplained fever who are responding to therapy 1
• In lower-risk patients meeting specific criteria who can tolerate oral medications, consider transition to oral antibiotics after initial response 1

Special Considerations in MDS

• Iron overload: Patients with significant transfusion burden may have elevated ferritin, which combined with monocytosis can suggest MDS itself as the fever source 4
• Pre-transplant patients: Those being considered for allogeneic stem cell transplantation require particularly aggressive infection management, as even moderate iron overload pre-transplant increases transplant-related mortality 1
• Higher-risk MDS subtypes (RAEB, RAEB-T) warrant heightened vigilance due to increased baseline infection risk 2